Post Traumatic Stress Disorder Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Post-Traumatic Stress Disorder (PTSD) Therapeutics Market Report is Segmented by Drug Class (SSRIs, Snris, Atypical Antipsychotics, and More), Patient Type (Adults, Children & Adolescents), Therapy Modality (Pharmacotherapy, Psychotherapy, and More), Distribution Channel (Hospital Pharmacies, and More), and Geography (North America, Europe and More). The Market Forecasts are Provided in Terms of Value (USD).

Post Traumatic Stress Disorder Market Size and Share

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Compare market size and growth of Post Traumatic Stress Disorder with other markets in Healthcare Industry

Post Traumatic Stress Disorder Market Analysis by Mordor Intelligence

The PTSD therapeutics market is valued at USD 19.04 billion in 2025 and is forecast to reach USD 24.74 billion by 2030, advancing at a 5.37% CAGR. The current expansion is anchored in the steady uptake of selective serotonin re-uptake inhibitors (SSRIs), the widening clinical footprint of psychedelic-assisted regimens, and the rapid commercialization of FDA-cleared digital therapeutics. Regulatory actions—most notably the August 2024 FDA rejection of MDMA therapy—have redirected capital toward combination pharmacology and software-as-a-medical-device solutions, preserving momentum despite setbacks. Companies are also leveraging AI-driven drug-repurposing engines to shorten development timelines while payers expand reimbursement for tele-psychiatry, widening access to underserved cohorts and reinforcing overall growth in the PTSD therapeutics market.

Key Report Takeaways

  • By drug class, SSRIs led with 39.56% of PTSD therapeutics market share in 2024, while psychedelic-assisted therapies are projected to rise at an 8.89% CAGR through 2030. 
  • By patient type, adults accounted for 81.78% of the PTSD therapeutics market size in 2024 and children & adolescents are expected to grow at 7.67% CAGR to 2030. 
  • By therapy modality, pharmacotherapy held 85.79% share of the PTSD therapeutics market size in 2024, whereas digital therapeutics are advancing at a 9.56% CAGR over the same period. 
  • By distribution channel, hospital pharmacies commanded 47.34% share in 2024; digital and tele-prescription platforms record the highest projected CAGR at 9.87% through 2030. 
  • By geography, North America led with 36.47% revenue share in 2024, while Asia-Pacific is forecast to expand at a 7.13% CAGR to 2030.

Segment Analysis

By Drug Class: SSRIs Steady, Psychedelics Surge

SSRIs retained a 39.56% slice of the PTSD therapeutics market in 2024 due to broad familiarity among prescribers and favorable safety records. Yet psychedelic-assisted approaches exhibit an 8.89% CAGR outlook, encouraged by adaptive trial designs and optimized safety protocols after the MDMA setback. Established SNRIs continue to serve treatment-resistant cases, and atypical antipsychotics such as brexpiprazole gain traction as combination agents.

The rise of NMDA receptor modulators, including esketamine approved in China, spotlights a shift toward glutamatergic pathways. Alpha-1 adrenergic antagonists and AI-identified repurposed drugs are also entering trials, enabled by faster de-risking. Developers able to integrate pharmacology with digital support will capture outsized value in the PTSD therapeutics market.

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By Patient Type: Adults Dominate, Pediatric Pipeline Accelerates

Adults contributed 81.78% of PTSD therapeutics market size in 2024 thanks to veteran and first-responder demand. Department of Veterans Affairs backing for psychedelic services further entrenches adult volume. Nonetheless, the pediatric cohort, while smaller, leads growth at 7.67% CAGR as early-intervention studies such as Tonix’s OASIS trial gain traction.

Digital platforms designed for youth engagement and caregiver oversight extend reach where in-person therapy is scarce, aligning with tele-health reimbursement reforms. Ethical barriers and smaller trial pools still temper near-term penetration, but tailored products will eventually lift pediatric uptake within the PTSD therapeutics market.

By Therapy Modality: Pharmacotherapy Holds Ground, Digital Outpaces

Legacy pharmacotherapy stood at an 85.79% share in 2024, underscoring entrenched prescribing behaviors and established reimbursement. However, digital therapeutics grow fastest at 9.56% CAGR, powered by devices like Freespira and game-based neurofeedback systems that achieve FDA clearance.

Combination platforms coupling medication with software and psychotherapeutic coaching are emerging as the optimal model to tackle the disorder’s multi-faceted symptom clusters. As insurer coverage expands, integrated offerings will re-shape revenue mix inside the PTSD therapeutics market.

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By Distribution Channel: Hospitals First, Virtual Scripts Rising

Hospital pharmacies processed 47.34% of prescriptions in 2024, reflecting the high acuity of initial PTSD presentations. Retail and specialty outlets continue serving refill demand, yet digital and tele-prescription portals are forecast to post a 9.87% CAGR through 2030.

DEA telemedicine reforms and partnerships such as NRx with Conversio Health for IV ketamine underscore the channel shift. Real-time safety checks embedded in e-prescribing platforms bolster compliance and extend market reach, fueling incremental gains for the PTSD therapeutics market.

Geography Analysis

North America led the PTSD therapeutics market with a 36.47% revenue share in 2024, supported by extensive clinical trial infrastructure, the largest veteran population, and progressive reimbursement for both drugs and software-as-medical-devices. The February 2025 FDA target date for brexpiprazole-sertraline approval and CMS reimbursement codes for digital PTSD tools position the region to remain the primary innovation hub.

Asia-Pacific is the fastest-growing territory, set to register a 7.13% CAGR to 2030. Japan’s clearance of smartphone-delivered cognitive therapy and China’s esketamine nod illustrate a regulatory climate increasingly receptive to novel modalities. Government programs that address mental-health stigma and invest in tele-health infrastructure will amplify patient reach in populous emerging economies, further expanding the PTSD therapeutics market.

Europe shows steady but evolving demand, with policymakers crafting frameworks for psychedelic adoption after Australia’s MDMA and psilocybin rollout. Pan-EU harmonization efforts aim to streamline approvals while maintaining stringent evidence thresholds. Fragmented local regulations still challenge market entry, but rising digital-therapy adoption and robust generic SSRI uptake keep the PTSD therapeutics market resilient across the continent.

Post Traumatic Stress Disorder CAGR (%), Growth Rate by Region
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Competitive Landscape

The PTSD therapeutics market remains moderately fragmented but is coalescing around three pillars: conventional pharma firms refining combination regimens, software companies securing 510(k) or De Novo clearances, and psychedelic developers navigating Schedule I hurdles. Pfizer and GSK maintain baseline revenue through generic SSRI portfolios, while Otsuka and Lundbeck pursue differentiated dual-agent offerings.

Strategic collaborations accelerate platform approaches: AbbVie’s USD 2 billion deal with Gilgamesh targets neuroplastogens that divorce efficacy from hallucinogenic effects, anticipating payer hesitancy over high-touch psychedelic protocols. AI specialists like Alto Neuroscience integrate biomarker-guided selection to boost trial success rates, creating a precision-medicine edge inside the PTSD therapeutics market.

Barriers to entry rise as stakeholders build controlled-setting infrastructures and specialized therapist networks. Intellectual-property filings—such as Lykos’s MDMA particle-size patents—underline the role of IP in securing competitive moats. Overall, sustainable leadership will hinge on offering cohesive solutions that fuse pharmacology, software, and psychotherapeutic services.

Post Traumatic Stress Disorder Industry Leaders

  1. Pfizer Inc.

  2. GlaxoSmithKline plc.

  3. Otsuka Pharmaceutical

  4. Jazz Pharmaceuticals

  5. Teva Pharmaceutical

  6. *Disclaimer: Major Players sorted in no particular order
graph template.png
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Need More Details on Market Players and Competitors?
Download PDF

Recent Industry Developments

  • May 2025: Tonix Pharmaceuticals dosed the first patient in the Phase 2 OASIS trial evaluating TNX-102 SL for acute stress reaction; the study is backed by a USD 3 million Department of Defense grant.
  • January 2025: The final Medicare physician fee schedule expands coverage for FDA-cleared digital PTSD therapies, broadening psychologist participation.
  • December 2024: JAMA Psychiatry published positive Phase 3 data for Otsuka/Lundbeck brexpiprazole-sertraline; FDA decision expected February 2025.
  • November 2024: FDA authorized a 320-patient Phase 2 trial of inhaled THC cannabis for veterans with moderate-to-severe PTSD.

Table of Contents for Post Traumatic Stress Disorder Industry Report

1. Introduction

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. Research Methodology

3. Executive Summary

4. Market Landscape

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Global PTSD Prevalence And Diagnosis Rates
    • 4.2.2 Accelerating Late-Stage Clinical Trials For Novel Agents
    • 4.2.3 Expedited FDA Breakthrough Therapy & Fast-Track Designations For Psychedelic-Assisted Therapies
    • 4.2.4 AI-Driven Drug-Repurposing Platforms Uncovering PTSD Indications For Existing CNS Drugs
    • 4.2.5 Government And Payer Uptake Of Digital Therapeutics For Post-Deployment Mental Health
    • 4.2.6 Expansion Of Tele-Psychiatry Increasing Prescription Reach In Underserved Regions
  • 4.3 Market Restraints
    • 4.3.1 Safety & Abuse-Liability Concerns Around Psychedelic Compounds
    • 4.3.2 High Placebo Responses In PTSD Trials Complicate Regulatory Approvals
    • 4.3.3 Limited Biomarker-Based Patient Stratification Reducing Drug Efficacy Signals
    • 4.3.4 Stigmatization And Under-Reporting Of Symptoms Curbing Treatment Uptake
  • 4.4 Value / Supply-Chain Analysis
  • 4.5 Regulatory Landscape
  • 4.6 Technology Outlook
  • 4.7 Porter’s Five Forces Analysis
    • 4.7.1 Bargaining Power of Suppliers
    • 4.7.2 Bargaining Power of Buyers
    • 4.7.3 Threat of New Entrants
    • 4.7.4 Threat of Substitutes
    • 4.7.5 Intensity of Competitive Rivalry

5. Market Size and Growth Forecasts (Value-USD)

  • 5.1 By Drug Class
    • 5.1.1 Selective Serotonin Re-uptake Inhibitors (SSRIs)
    • 5.1.2 Serotonin-Norepinephrine Re-uptake Inhibitors (SNRIs)
    • 5.1.3 Atypical Antipsychotics
    • 5.1.4 Alpha-1 Adrenergic Antagonists
    • 5.1.5 NMDA Receptor Modulators
    • 5.1.6 Psychedelic-assisted Therapies (MDMA, Psilocybin, LSD)
    • 5.1.7 Other Classes (Beta-blockers, Benzodiazepines, Anticonvulsants)
  • 5.2 By Patient Type
    • 5.2.1 Adults
    • 5.2.2 Children & Adolescents
  • 5.3 By Therapy Modality
    • 5.3.1 Pharmacotherapy
    • 5.3.2 Psychotherapy
    • 5.3.3 Digital Therapeutics
    • 5.3.4 Combination Therapy
  • 5.4 By Distribution Channel
    • 5.4.1 Hospital Pharmacies
    • 5.4.2 Retail & Specialty Pharmacies
    • 5.4.3 Digital / Tele-prescription Platforms
  • 5.5 By Geography
    • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
    • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
    • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 Australia
    • 5.5.3.5 South Korea
    • 5.5.3.6 Rest of Asia-Pacific
    • 5.5.4 Middle East and Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East and Africa
    • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6. Competitive Landscape

  • 6.1 Market Concentration
  • 6.2 Market Share Analysis
  • 6.3 Company profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products and Services, and Recent Developments)
    • 6.3.1 Pfizer
    • 6.3.2 GlaxoSmithKline
    • 6.3.3 Otsuka Pharmaceutical
    • 6.3.4 Lundbeck
    • 6.3.5 Jazz Pharmaceuticals
    • 6.3.6 Teva Pharmaceutical
    • 6.3.7 Viatris
    • 6.3.8 Tonix Pharmaceuticals
    • 6.3.9 Compass Pathways
    • 6.3.10 Multidisciplinary Association for Psychedelic Studies (MAPS PBC)
    • 6.3.11 Mydecine Innovations Group
    • 6.3.12 Alto Neuroscience
    • 6.3.13 BioXcel Therapeutics
    • 6.3.14 Transcend Therapeutics
    • 6.3.15 Lupin
    • 6.3.16 Merck KGaA
    • 6.3.17 Johnson & Johnson (Janssen)
    • 6.3.18 Aurobindo Pharma
    • 6.3.19 Clearmind Medicine

7. Market Opportunities and Future Outlook

  • 7.1 White-Space and Unmet-Need Assessment
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Global Post Traumatic Stress Disorder Report Scope

As per the scope of the report, post-traumatic stress disorder (PTSD) is referred to as a mental health condition that's triggered by a terrifying event, either experiencing it or witnessing it. The treatment of PTSD includes the use of certain medications. The Post Traumatic Stress Disorder Treatment market is segmented by Drug Class (Antidepressants, Anti-anxiety drugs, Antipsychotics, and Other Drug Classes), By Patient (Adult and Children), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Other Distribution Channels) and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.

By Drug Class Selective Serotonin Re-uptake Inhibitors (SSRIs)
Serotonin-Norepinephrine Re-uptake Inhibitors (SNRIs)
Atypical Antipsychotics
Alpha-1 Adrenergic Antagonists
NMDA Receptor Modulators
Psychedelic-assisted Therapies (MDMA, Psilocybin, LSD)
Other Classes (Beta-blockers, Benzodiazepines, Anticonvulsants)
By Patient Type Adults
Children & Adolescents
By Therapy Modality Pharmacotherapy
Psychotherapy
Digital Therapeutics
Combination Therapy
By Distribution Channel Hospital Pharmacies
Retail & Specialty Pharmacies
Digital / Tele-prescription Platforms
By Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
By Drug Class
Selective Serotonin Re-uptake Inhibitors (SSRIs)
Serotonin-Norepinephrine Re-uptake Inhibitors (SNRIs)
Atypical Antipsychotics
Alpha-1 Adrenergic Antagonists
NMDA Receptor Modulators
Psychedelic-assisted Therapies (MDMA, Psilocybin, LSD)
Other Classes (Beta-blockers, Benzodiazepines, Anticonvulsants)
By Patient Type
Adults
Children & Adolescents
By Therapy Modality
Pharmacotherapy
Psychotherapy
Digital Therapeutics
Combination Therapy
By Distribution Channel
Hospital Pharmacies
Retail & Specialty Pharmacies
Digital / Tele-prescription Platforms
By Geography
North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Key Questions Answered in the Report

1. What is the current size of the PTSD therapeutics market?

The PTSD therapeutics market is valued at USD 19.04 billion in 2025 and is projected to reach USD 24.74 billion by 2030.

2. Which drug class holds the largest PTSD therapeutics market share?

SSRIs led with a 39.56% PTSD therapeutics market share in 2024.

3. Which therapy modality is growing fastest?

Digital therapeutics are forecast to expand at a 9.56% CAGR between 2025 and 2030.

4. Why did the FDA reject MDMA therapy for PTSD?

Regulators cited safety concerns and functional unblinding, requesting an additional Phase 3 trial before reconsideration.

5. Which region is expanding most rapidly?

Asia-Pacific is expected to register a 7.13% CAGR, driven by regulatory modernization and growing mental-health awareness.

6. How are tele-prescription platforms impacting the PTSD therapeutics industry?

DEA telemedicine reforms and new Medicare codes allow controlled PTSD medications and digital therapies to be prescribed virtually, supporting a 9.87% CAGR in the channel.

Page last updated on: July 4, 2025

Post Traumatic Stress Disorder Report Snapshots